Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
98.25
0.00 (0.00%)
Nov 21, 2024, 4:00 PM EST
Novartis AG Revenue
Novartis AG had revenue of $13.17B in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
49.94B
Revenue Growth
+8.92%
P/S Ratio
n/a
Revenue / Employee
656.61K
Employees
76,057
Market Cap
206.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
Novartis AG News
- 2 days ago - Novartis ranks first in 2024 Access to Medicine Index - GlobeNewsWire
- 3 days ago - Novartis, Ratio to collaborate on SSTR2 radiotherapeutic for cancer - Seeking Alpha
- 3 days ago - Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate - PRNewsWire
- 8 days ago - PPI, Novartis hold media workshop to enhance health literacy in managing cholesterol, promote heart health - BusinessMirror
- 9 days ago - Schrödinger gains on Novartis deal despite Q3 miss - Seeking Alpha
- 9 days ago - Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details - Benzinga
- 9 days ago - Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer - Business Wire
- 9 days ago - Schrödinger’s stock soars 9% as it enters collaboration pact with Novartis for up to about $2.5 billion in payments - MarketWatch